Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy of dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin derivatives). The anticipated degree of improvement in the safety of anticoagulation with coumarins through genotyping may vary depending on the quality of patient care, which varies both with and among countries. The management and the cost of anticoagulant care can therefore influence the cost-effectiveness of genotyping within any given country. In this article, we provide an overview of the cost-effectiveness of pharmacogenetics-guided dosing of coumarin derivatives. We describe the organization of anticoagulant care in the UK, Sweden, The Netherlands, Greece, Germany and Austria, where a genotype-guided dosing algorithm is currently being investigated as part of the EU-PACT trial. We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries.

Additional Metadata
Keywords acenocoumarol, atrial fibrillation, cost analysis, coumarins, health economics, healthcare system, phenprocoumon, warfarin
Persistent URL dx.doi.org/10.2217/pgs.12.124, hdl.handle.net/1765/37319
Journal Pharmacogenomics
Grant This work was funded by the European Commission 7th Framework Programme; grant id fp7/223062 - A pharmacogenomic approach to coumarin anticoagulant therapy (EU-PACT)
Citation
Verhoef, T.I, Redekop, W.K, van Schie, R.F.M, Bayat, S, Daly, A.K, Geitona, M, … Maitland-van der Zee, A-H. (2012). Cost-effectiveness of pharmacogenetics in anticoagulation. Pharmacogenomics (Vol. 13, pp. 1405–1417). doi:10.2217/pgs.12.124